ROME Therapeutics logo

ROME Therapeutics Funding & Investors

ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as β€œjunk DNA.” With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier in biology. To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning.

rometx.com

Total Amount Raised: $199,000,000

ROME Therapeutics Funding Rounds

  • Series B

    $72,000,000

    Series B Investors

    Alexandria Venture Investments
    Sigmas Group
    Johnson & Johnson Innovation
    ArchVentures
    Bristol-Myers Squibb
    Andreessen Horowitz
    Axon Ventures
    Mirae Asset Capital
    Sanofi Ventures
    Section 32
    Casdin Capital
    Mass General Brigham Ventures
    LUMA Group
    GV
    RS Participaties
    Curie.Bio
  • Series B

    $77,000,000

    Series B Investors

    Section 32
    Sanofi Ventures
    Alexandria Venture Investments
    GV
    Arch Venture Partners
    Casdin Capital
    Andreessen Horowitz
    Mass General Brigham Ventures
  • Series A

    $50,000,000

    Series A Investors

    GV
    Partners Innovation Fund
    Arch Venture Partners
Funding info provided by Diffbot.